×
About 16,358 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  5,996 results

Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1.
https://doi.org/10.1186/s13073-021-01006-6 10.1038/nature20413 10.1212/NXG.0000000000000398 10.1038/ng.3622 10.1038/s41467-017-00471-1 10.1038/ng.3211 10.1038/ng.3955 10.1038/ncomms14774 10.1038/ng.3626 10.1016/j.neuron.2018.02.027 10.1038/s42003-020-01251-2 10.1016/j.celrep.2020.108323 10.1038/nature22366 10.1038/s41586-020-2188-x 10.1007/s00415-013-6877-3 10.1038/nature16549 10.1016/j.ajhg.2013.10.012 10.1038/nn.4587 10.1038/ng.3538 10.1038/s41467-017-01261-5 10.1038/s41467-019-11181-1 10.1038/ng.3404 10.1038/s41588-018-0081-4 10.1038/nature15393 10.1371/journal.pcbi.1004219 10.1093/bioinformatics/btr260 10.1126/science.aat8127 10.1038/mp.2013.93 10.1038/nature11247 10.1038/nature14248 10.1038/nature24277 10.1038/s41588-018-0089-9 10.1038/ng.2213 10.1038/s41467-018-04558-1 10.1038/nn.4399 10.1038/nn.4632 10.1111/j.1471-4159.2011.07432.x 10.1126/science.aat8464 10.1038/ng.3506 10.1093/bioinformatics/btw198 10.1016/j.clinph.2020.04.005 10.1038/s41525-020-0118-3 10.1371/journal.pone.0198874 10.1371/journal.pgen.0030161 10.1126/science.282.5391.1145 10.1038/ncomms7626 10.1111/bph.14657 10.1371/journal.pone.0018373 10.1038/s41467-018-06111-6 10.1016/j.jns.2005.02.004 10.1083/jcb.200304128 10.1038/nm.2901 10.1002/ana.23946 10.1212/NXI.0000000000000829 10.1093/brain/awy353 10.1093/nar/gky837 10.1371/journal.pgen.1002431 10.1073/pnas.95.25.14863 10.1038/s41588-021-00913-z 10.1016/j.bbadis.2010.09.011 10.4103/1673-5374.241445 10.3892/ijmm.2017.3049 10.1016/0891-5849(94)90079-5 10.1074/jbc.274.15.10349 10.1016/j.stemcr.2018.04.020 10.1038/s41591-018-0140-5 10.1016/j.neuron.2019.07.014 10.1074/jbc.M401907200 10.1038/nn.3801 10.1172/JCI118522 10.1042/cs0830343 10.1161/CIRCULATIONAHA.110.000034 10.3389/fncel.2015.00203 10.1016/j.bbadis.2006.03.008 10.3390/ijms15022475 10.1007/s00401-005-1019-3 10.1038/s41467-018-04114-x 10.1016/j.ebiom.2020.102980 10.1038/s41586-020-2308-7 10.1016/S1474-4422(13)70061-9 10.1016/j.omtn.2019.02.001
Genome Medicine; Restuadi R, Steyn FJ et. al.

Jan 20th, 2022 - Amyotrophic lateral sclerosis (ALS) is a complex, late-onset, neurodegenerative disease with a genetic contribution to disease liability. Genome-wide association studies (GWAS) have identified ten risk loci to date, including the TNIP1/GPX3 locus ...

Diaphragm ultrasonography as a tool in assessing respiratory muscle involvement in amyo...
https://doi.org/10.1002/jcu.23093
Journal of Clinical Ultrasound : JCU; Bongioanni P

Jan 20th, 2022 - Diaphragm ultrasonography as a tool in assessing respiratory muscle involvement in amyotrophic lateral sclerosis/motor neuron disease.|2022|Bongioanni P,|

Integrated genome and transcriptome analyses reveal the mechanism of genome instability...
https://doi.org/10.1073/pnas.2114314119
Proceedings of the National Academy of Sciences of the Un... Kanagaraj R, Mitter R et. al.

Jan 20th, 2022 - Mutations in the SETX gene, which encodes Senataxin, are associated with the progressive neurodegenerative diseases ataxia with oculomotor apraxia 2 (AOA2) and amyotrophic lateral sclerosis 4 (ALS4). To identify the causal defect in AOA2, patient-...

Mutation screening of the DNAJC7 gene in Japanese patients with sporadic amyotrophic la...
https://doi.org/10.1016/j.neurobiolaging.2021.12.002
Neurobiology of Aging; Tohnai G, Nakamura R et. al.

Jan 19th, 2022 - DNAJC7 has recently been identified as an amyotrophic lateral sclerosis (ALS) gene via large-scale exome analysis, and its involvement in ALS is still unclear in various populations. This study aimed to determine the frequencies and characteristic...

see more →

Guidelines  3 results

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

ESPEN guideline clinical nutrition in neurology.
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  184 results

A Study of BIIB067 When Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
https://clinicaltrials.gov/ct2/show/NCT04856982

Jan 14th, 2022 - The primary objective of this study is to evaluate the efficacy of BIIB067 when initiated in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to ...

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
https://clinicaltrials.gov/ct2/show/NCT02437110

Jan 13th, 2022 - Objective: In this Phase I, proof-of-concept study, we aim to determine whether an antiretroviral regimen approved to treat human immunodeficiency virus (HIV) infection would also suppress levels of Human Endogenous Retrovirus-K (HERV-K) found to ...

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
https://clinicaltrials.gov/ct2/show/NCT04569084

Jan 12th, 2022 - To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale- Revised (ALSFRS-R) score from baseline up to Week 48:

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
https://clinicaltrials.gov/ct2/show/NCT05178810

Jan 5th, 2022 - Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.

Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing
https://clinicaltrials.gov/ct2/show/NCT04394871

Dec 16th, 2021 - Objective: Amyotrophic lateral sclerosis type 4 (ALS4) is an inherited form of motor neuron disease caused by mutation in the senataxin (SETX) gene. The main goal of this study will be to collect clinical and molecular biomarkers from patients wit...

see more →

News  334 results

Long-Term Adjunctive Edaravone for ALS: Latest Findings
https://www.medscape.com/viewarticle/966717

Jan 17th, 2022 - Dr Simon Witzel Long-term add-on treatment with intravenous (IV) edaravone is not associated with any change in the progression of amyotrophic lateral sclerosis (ALS), new research shows. These findings contradict those from the drug trial the US ...

Long NFL Careers Significantly Boost ALS Risk, but What's at Play?
https://www.medscape.com/viewarticle/964853

Dec 15th, 2021 - National Football League players are nearly four times more likely to develop amyotrophic lateral sclerosis (ALS) than men in the general population, with long-term players at greatest risk, a new study shows. The findings are the latest to show i...

HCQ and MS; Guillain-Barre and COVID Vax; Neural Fingerprints Can Tell Who You Are
https://www.medpagetoday.com/neurology/generalneurology/95120

Oct 19th, 2021 - The antimalarial drug hydroxychloroquine (HCQ) was associated with reduced disability worsening in people with primary progressive multiple sclerosis (MS), a phase II trial showed. (Annals of Neurology) The FDA approved injectable high-dose naloxo...

ALS-Lipids Link, Eye Disease and Heightened Dementia Risk; Parkinson's and NSAIDs
https://www.medpagetoday.com/neurology/generalneurology/94613

Sep 21st, 2021 - Elevated levels of HDL and apolipoprotein A1 were linked to a lower risk of amyotrophic lateral sclerosis (ALS), U.K. Biobank data showed. (Journal of Neurology, Neurosurgery, & Psychiatry) Also from the U.K. Biobank cohort: age-related macular de...

Lipid Levels Tied to ALS Risk
https://www.medscape.com/viewarticle/958730

Sep 14th, 2021 - Elevated levels of high-density lipoprotein (HDL) and apolipoprotein A1 (apoA1) are associated with a reduced risk for amyotrophic lateral sclerosis (ALS), new research shows. The study also linked a higher ratio of total cholesterol to HDL with a...

see more →

Patient Education  9 results see all →